TABLE 2.
Patients’ baseline characteristics.
| Characteristics | Overall (n = 12) |
| Age (mean years ± SD) | 73 ± 5 |
| Female sex [n/total n (%)] | 5/12 (42) |
| BMI (mean Kg/m2 ± SD) | 23 ± 3 |
| Systolic blood pressure (mean mmHg ± SD) | 112 ± 12 |
| Diastolic blood pressure (mean mmHg ± SD) | 66 ± 8 |
| Heart rate (mean ± SD) | 74 ± 12 |
| Medical history [n/total n (%)] | |
| HFrEF | 1/12 (8) |
| HFpEF | 0/12 (0) |
| Prior PCI | 2/12 (17) |
| Prior CABG | 1/12 (8) |
| Risk factors | |
| Hypertension [n/total n (%)] | 7/12 (58) |
| Diabetes mellitus [n/total n (%)] |
1/12 (8) |
| Dyslipidaemia [n/total n (%)] | 3/12 (25) |
| Smoker [n/total n (%)] | 0/12 (0) |
| CHADS-VASc (mean ± SD) | 3 ± 1 |
| HAS-BLED (mean ± SD) | 2 ± 1 |
| Echocardiography at enrollment [mean ± SD (n)] | |
| LVEF (%) | 59 ± 10 (5) |
| E/A | 0.9 ± 0.6 (3) |
| E/E’ | 8.2 ± 2.0 (4) |
| Full blood count and coagulation at baseline (mean ± SD) | |
| Haemoglobin (g/dl) | 11.1 ± 2.4 |
| Red blood cell count (×10^12/l) | 3.8 ± 0.8 |
| White blood cell count (×10^9/l) | 7.4 ± 3.1 |
| Neutrophils (%) | 65.7 ± 9.7 |
| Lymphocytes (%) | 25.1 ± 9.5 |
| Monocytes (%) | 6.5 ± 2.0 |
| Platelet count (×10^9/l) | 300 ± 133 |
| aPPT (second) | 38 ± 4 |
| INR | 1.1 ± 0.1 |
| Fibrinogen (mg/dl) | 424 ± 115 |
| Blood chemistry at baseline (mean ± SD) | |
| Glucose (mg/dl) | 114 ± 31 |
| Total cholesterol (mg/dl) | 147 ± 39 |
| HDL (mg/dl) | 43 ± 14 |
| LDL (mg/dl) | 88 ± 35 |
| TGL (mg/dl) | 133 ± 104 |
| ALT (Ul/l) | 17 ± 8 |
| AST (Ul/l) | 16 ± 4 |
| LDH (Ul/l) | 146 ± 34 |
| Albumin (g/l) | 31 ± 5 |
| Cystatin C (mg/l) | 1.8 ± 0.6 |
| Pharmacotherapy at baseline [n/total n (%)] | |
| Previous VKA | 0/12 (0) |
| Previous DOAC | 4/12 (33) |
| ASA | 1/12 (8) |
| P2Y12 inhibitor | 1/12 (8) |
| Statin | 3/12 (25) |
| Beta-blocker | 7/12 (58) |
| Ca2+ channel blocker | 1/12 (8) |
| Diuretic | 9/12 (75) |
| Insulin | 1/12 (8) |
| ACEi/ARB | 1/12 (8) |
| Condition leading to the PEG procedure (n/total n) | |
| ALS | 10/12 |
| Steinert myotonic dystrophy | 1/12 |
| Ischemic stroke | 1/12 |
| Edoxaban dose (n/total n) | |
| Edoxaban 60 mg | 1/12 |
| Edoxaban 30 mg due to eGFR 15–50 mL/min/1.73 m2 | 5/12 |
| Edoxaban 30 mg due to body weight < 60 Kg | 6/12 |
BMI, body mass index; ALS, amyotrophic lateral sclerosis; AF, atrial fibrillation; CAD, coronary artery disease; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; LVEF, left ventricular ejection fraction; PT, prothrombin time; INR, international normalized ratio; HDL, high density lipoprotein; LDL, low density lipoprotein; TGL, triglycerides; ALT, alanine transaminase; AST, aspartate transaminase; LDH, lactate dehydrogenase; ASA, acetyl salicylic acid; ACEi, angiotensin-converting-enzyme inhibitors; ARB, angiotensin II receptor blockers.